Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Technology

ImotopesTM: Next Generation
Immunotherapeutics

With the ImotopeTM platform, we are developing next generation immunotherapies that have the potential to address a wide range of indications in the field of immunology and beyond. Our initial focus is on severe, chronic autoimmune diseases where our pioneering approach could prevent, treat and potentially cure some of the most challenging and underserved areas of modern medicine.

The ImotopeTM Technology

The challenge of current therapies

Autoimmune disorders occur when the body’s immune system mistakenly attacks the body’s cells and tissues. Few therapies address the underlying causes of the disease (disease modifying) and those that do often cause a generalized immune suppression with significant side effects. While this general suppression does dampen the autoimmune attack, it also weakens the immune system to the point that it cannot mount a proper response leading to severe side effects such as the inability to fight infection or control cancers. They can also require daily medication or periodic hospital infusions.

The side effects from some of the treatments are so severe that many patients stop treatment (ref).

Most other drugs simply alleviate the symptoms or temporarily halt the immune attack.

For most of the more than 80 autoimmune disorders, however, there are no cures and in- novation is needed.

Current therapies are generally:

STEROID

ANTIBODIES
F.e. against anti CD19 or CD20 positive cells or certain immune modulators such as anti TNF antibodies

PEPTIDES,
PROTEINS & SMALL MOLECULES

CELL BASED THERAPIE

ImotopesTM – a new solution

ImotopesTM stimulate T cells that specifically target the autoimmune pathway without affecting the rest of the immune system. The specific cytolytic CD4+ T cells induced by ImotopesTM knock out cells involved in the pathogenic pathway and therefore stop the autoimmune attack. This prevents further tissue damage, and halts disease progression.

ImotopesTM also induce memory cytolytic CD4+ T cells, which provide long-lasting treatment effects with infrequent dosing.

    The challenges of current therapies

    Our ImotopesTM a new solution

  • Unspecific – cause a generalized immune suppression of both the disease pathways but also the important pathways of the immune system

    Antigen specific – ImotopesTM suppress
    the disease pathway which allows for highly effective tailored therapy

  • Significant side effects – such as immune suppression, increased risk of infection and inability to control cancer

    Good Safety Profile – targeting the disease pathway only we leave the rest of the immune function

  • Require frequent dosing – often requires daily medication or periodic hospital based infusions

    Long lasting – ImotopesTM are administered like a vaccine, inducing long lasting effects through the induction of memory cells

  • Difficult and expensive to manufacture

    Although highly specific, ImotopesTM are short peptides made with standard pharmaceutical processes, easily synthesized and stable.
    They do not have the challenges of therapies such as cell based products

Broad applicability

In addition to autoimmune diseases, Imcyse’s technology has potential in allergy, cancer and other diseases.

The technology could also be applied as an “add-on” therapy to other drugs or biologics to prevent the progression of immunogenicity and loss of efficacy with chronic administra- tion - such as with monoclonal antibodies or replacement enzymes. Furthermore, it may eliminate the immune response against the viral vectors that are used in gene therapies.

Glossary

1. Processing: APCs absorb proteins from the local environment, cleave the amino acid strings into sort segments and load them on the MHCII “moiety” which is then ex- pressed on the cell surface.

2. Epitope is the sequence of the autoantigen which is recognized by the immune system and causes an aberrant immune reaction by binding to the MHCII and stimulates the TCR

3. Thioredox, Thioredox motif is a sequence of amino acids which has the ability to re- duce protein bonds, the sequence is based on an enzyme called thioredoxin and is a key element giving our drugs their activity

Publications

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Hoc mihi cum tuo fratre convenit. Sedulo, inquam, faciam. Iam id ipsum absurdum, maximum malum neglegi. Deinde dolorem quem maximum?

Sed fortuna fortis; Universa enim illorum ratione cum tota vestra confligendum puto. Quis est tam dissimile homini. Primum in nostrane potestate est, quid meminerimus? Facile est hoc cernere in primis puerorum aetatulis.

Non quam nostram quidem, inquit Pomponius iocans; Qui est in parvis malis. Hoc non est positum in nostra actione. Et quod est munus, quod opus sapientiae?

Posters

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Hoc mihi cum tuo fratre convenit. Sedulo, inquam, faciam. Iam id ipsum absurdum, maximum malum neglegi. Deinde dolorem quem maximum?

Sed fortuna fortis; Universa enim illorum ratione cum tota vestra confligendum puto. Quis est tam dissimile homini. Primum in nostrane potestate est, quid meminerimus? Facile est hoc cernere in primis puerorum aetatulis.

Non quam nostram quidem, inquit Pomponius iocans; Qui est in parvis malis. Hoc non est positum in nostra actione. Et quod est munus, quod opus sapientiae?

Further resources

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Hoc mihi cum tuo fratre convenit. Sedulo, inquam, faciam. Iam id ipsum absurdum, maximum malum neglegi. Deinde dolorem quem maximum?

Sed fortuna fortis; Universa enim illorum ratione cum tota vestra confligendum puto. Quis est tam dissimile homini. Primum in nostrane potestate est, quid meminerimus? Facile est hoc cernere in primis puerorum aetatulis.

Non quam nostram quidem, inquit Pomponius iocans; Qui est in parvis malis. Hoc non est positum in nostra actione. Et quod est munus, quod opus sapientiae?

©imcyse 2022